High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(CO)). RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). CONCLUSIONS: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, a recent trial with high doses of the antioxidant acetylcysteine appeared to attenuate the progression of IPF (25).”
From Adult-onset pulmonary fibrosis caused by mutations in telomerase (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)”
BackgroundGross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 3×
“Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)”
BackgroundChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 1×
“Respiratory tract infection† 22 20 (25) 27 24 (32)”
Research works printed but not linked: 6
- 15. thione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:431-6.
- 29. Quanjer PH. Standardized lung function testing: report of working party. Bull Eur Physiopathol Respir 1983;19:Suppl 5:195.
- 30. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1-100.
- 12. functional trends. Am J Respir Crit Care Med 2003;168:531-7.
- 37. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH guidelines: 'efficacy' topics. E6. Good clinical practice: consolidated guideline. (Accessed October 28, 2005, at http://www. ich.org/cache/compo/276-254-1.html.)
- 23. vival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
Cited by
Items 601–700 of 960
Advances in the management of idiopathic pulmonary fibrosis
Ryu, J. H., & Daniels, C. E. (2010) · F1000 Medicine Reports · doi:10.3410/m2-28 · Cited by 10
Heili-Frades, S. B., del Puerto‐Nevado, L., Pérez-Rial, S., Martín-Mosquero, C., Ortega, M., Martínez-Galán, L., Rubio, M. L., Nieto, M. J. R., González‐Mangado, N., & Romero, G. P.-B. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.05026.x · Cited by 9
“This explains the favourable effects of high doses of NAC on lung function in patients with idiopathic pulmonary fibrosis.(25) Evidence of oxidative stress induced by CdCl2 11,12 favours the use of anti-oxidant treatment as a possible therapeutic tool.”
BackgroundUpdate in Diffuse Parenchymal Lung Disease 2011
Luckhardt, T., Müller–Quernheim, J., & Thannickal, V. J. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0509up · Cited by 11
“Triple therapy with prednisone, azathioprine, and N-acetylcysteine was recommended in the 2008 guidelines on IPF of the British Thoracic Society (10), based largely on a 2005 study that demonstrated benefit when N-acetylcysteine was added to a combination of prednisone and azathioprine (11); however, more recent studi…”
BackgroundHistological appearances of putative montelukast related Churg-Strauss syndrome
Currie, G. P., McKinlay, L., & Kerr, K. M. (2008) · Thorax · doi:10.1136/thx.2008.102566 · Cited by 9
IL-10: another therapeutic target in idiopathic pulmonary fibrosis?
Millar, A. (2006) · Thorax · doi:10.1136/thx.2006.060772 · Cited by 9
(2024) · Springer eBooks · doi:10.1007/978-981-99-9283-6_1305 · Cited by 9
Allameh, Z. S., Karimi, A., Tabatabaei, S. R., Sharifian, M., & Salamzadeh, J. (2015) · Iranian Journal of Kidney Diseases · Cited by 8
The diagnosis of idiopathic pulmonary fibrosis and its complications
Maher, T. M. (2008) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530050802549484 · Cited by 8
“So far, the most encouraging of these has been the IFGENIA study, which demonstrated a slowing in disease progression, as measured by lung function, in patients treated with the antioxidant N -acetylcysteine [146] .”
A one-year follow-up study of patients survived after ALI / ARDS caused by influenza A / H1N1
Avdeev, S. N., Karchevskaya, N. A., Baimakanova, G. E., & Cherniak, A. V. (2011) · PULMONOLOGIYA · doi:10.18093/0869-0189-2011-0-4-58-66 · Cited by 8
Clinical Trials in IPF: What Are the Best Endpoints?
Spagnolo, P., Cocconcelli, E., & Cottin, V. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_19 · Cited by 9
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
Gorini, F., Santoro, M. C., Pierini, A., Mezzasalma, L., Baldacci, S., Bargagli, E., Boncristiano, A., Brunetto, M. R., Cameli, P., Cappelli, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869842 · Cited by 8
“IPF is a chronic, progressive, fibrosing interstitial pneumonia (Maher and Strek, 2019).”
BackgroundInfluentialFibrose pulmonaire idiopathique
Cordier, J.-F. (2009) · La Presse Médicale · doi:10.1016/j.lpm.2009.10.009 · Cited by 9
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study
Brown, K. M., & Wells, A. U. (2008) · European Respiratory Review · doi:10.1183/09059180.00010903 · Cited by 8
“approaches to IPF and include, in addition to the BUILD-1 trial [6], the European Idiopathic Pulmonary Fibrosis International Group Exploring N-acetylcysteine 1 Annual (IFIGENIA) trial [ 7 ] and the interferon (IFN) gamma GIPF-001 trial [8], as well as trials on anticoagulant therapy [9], pirfenidone [10] and etanerce…”
MethodInfluentialNovelty in Treatment of Pulmonary Fibrosis: Pulmonary Hypertension Drugs and Others
Correale, M., Totaro, A., Lacedonia, D., Montrone, D., Biase, M. D., Barbaro, M. P. F., & Brunetti, N. D. (2014) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152571131100086 · Cited by 8
Successful treatment of non-healing pressure ulcers with topical n-acetyl cysteine
Özkaya, H., Bahat, G., Tufan, A. E., Dogan, H., Bilicen, Z., & Karan, M. A. (2015) · Journal of Wound Care · doi:10.12968/jowc.2015.24.12.606 · Cited by 8
Year in review 2012: Acute lung injury, interstitial lung diseases, sleep and physiology
Eves, N. D., Song, Y., Piper, A. J., & Maher, T. M. (2013) · Respirology · doi:10.1111/resp.12053 · Cited by 8
Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib
Hayton, C., & Chaudhuri, N. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17719126 · Cited by 10
Pang, Q., Li, G., Cao, F., Liu, H., Wei, W., & Jiao, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265006 · Cited by 8
“demonstrated that NAC could have some beneficial effects on percentage of predicted carbon monoxide diffusing capacity (DLCO (%)) in the patients with IPF [4].”
BackgroundDiffuse parenchymal lung disease
Maher, T. M. (2012) · Medicine · doi:10.1016/j.mpmed.2012.03.007 · Cited by 16
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Kim, D. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11454-0 · Cited by 8
Zhang, X.-L., Cao, Y., & Zheng, B. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02778-w · Cited by 7
“NAC has been shown to enhance glutathione synthesis, regulate lysine oxidase activity, inhibit epithelial-mesenchymal transformation, and ultimately reduce the presence of oxygen free radicals and provide antioxidant effects [11, 31–33].”
BackgroundInfluentialFroidure, A., Joannes, A., Mailleux, A., & Crestani, B. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1171140 · Cited by 7
“used with immunosuppressive agents.[20] However, a randomized trial, comparing prednisone, azathioprine, and NAC”
BackgroundFibrose pulmonaire: dans quels cas et sur quels critères envisager une admission en réanimation ?
Mullier, A., Cottin, V., Richard, J., & Guérin, C. (2012) · Réanimation · doi:10.1007/s13546-012-0642-y · Cited by 8
“placebo un bénéfice de la N-acétylcystéine sur l’évolution de la capacité vitale et du transfert du monoxyde de carbone [17].”
Jackson, R. M., & Gómez-Marín, O. (2011) · Transplant Research and Risk Management · doi:10.2147/trrm.s16205 · Cited by 9
“28 That finding suggested the importance of redox signaling in IPF progression.”
Updates in the Diagnosis and Treatment of Vasculitis
Sakkas, L. I., & Katsiari, C. G. (2013) · InTech eBooks · doi:10.5772/46068 · Cited by 8
Altered Tregs and oxidative stress in pregnancy associated lupus
Pannu, N., Singh, R., Sharma, S. K., Chopra, S., & Bhatnagar, A. (2019) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-019-0082-8 · Cited by 7
Rind, L., Ahmad, M., Khan, M. I., Badruddeen, B., Akhtar, J., Ahmad, U., Yadav, C., & Owais, M. (2021) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2020-0099 · Cited by 8
Corrêa, M. J. U., Mariz, H. D. A., Andrade, L. E. C., & Kayser, C. (2014) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2014.09.001 · Cited by 9
Roig, V., Herrero, A., Arroyo-Cózar, M., Vielba, D., Martínez, S. A. J., & Macías, E. (2009) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2009.09.015 · Cited by 7
Raghu, G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00092-0 · Cited by 9
Tang, C., Wang, L., Chen, Z., Shi, X., Chen, Y., Jin, Y., Gao, H., Guan, C., He, S., Zhang, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094203 · Cited by 6
“As a commonly used antioxidant, it has been clinically used to treat early-stage ILD patients [13–15].”
Farzandway, M., Komi, D. E. A., Noori, E. M., Goudarzi, F., Ahmadabad, R. A., Eshraghi, A., Mirzaasgari, Z., Navabi, S. M., & Kiani, A. (2023) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-023-00380-x · Cited by 6
“NAC has been at the center of attention due to its effectiveness in some pathologies and diseases in humans such as the prevention of chronic obstructive pulmonary disease (COPD) exacerbation [18], prevention of contrast-induced nephropathy during the imaging process [19], improving the health condition in influenza v…”
BackgroundNewer modes of treating interstitial lung disease
Wuyts, W. A., Thomeer, M., & Demedts, M. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283483e76 · Cited by 6
Self-citationApplication of N-Acetylcysteine in Pulmonary Disorders
Conrad, C. (2018) · Springer eBooks · doi:10.1007/978-981-10-5311-5_15 · Cited by 6
Naimi, M., Shariati, M., Naimi, S., & Edalatmanesh, M. (2019) · European Journal of Biology · doi:10.26650/eurjbiol.2019.0009 · Cited by 6
Aspectos relevantes en el manejo de la enfermedad pulmonar intersticial difusa
Fernandez, D. I., Sánchez, R. P., Moreno, A. F., & Fabrellas, E. F. (2009) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(09)72851-0 · Cited by 6
Update on models of pulmonary fibrosis therapy for preclinical drug research
Antoniu, S. A., & Kolb, M. R. J. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903186100 · Cited by 10
“This randomized, placebo-controlled study performed in 182 patients suggested that addition of NAC to the conventional therapy significantly slowed lung function decline (vital capacity and diffusion capacity) after 1 year, although it had no significant effect on survival as compared to conventional therapy alone [54…”
Exacerbation of Pulmonary Fibrosis Following Single Lung Transplantation
Yang, D., Wilson, J. M., Bai, C., Yee, J., Wilcox, P., Khalil, N., & Levy, R. D. (2012) · Canadian Respiratory Journal · doi:10.1155/2012/258485 · Cited by 6
“The left lung opacification improved following institution of pulse prednisone and N-acetylcysteine (1D, day 60, following 45 days augmented prednisone + N-acetylcysteine”
BackgroundInfluentialMehrabi, S., Moradi, M. M., Khodamoradi, Z., & Nazarinia, M. A. (2019) · Current Rheumatology Reviews · doi:10.2174/1573397115666191212092608 · Cited by 7
Novel Aspects of Treatment for Interstitial Lung Diseases
Behr, J. (2007) · KARGER eBooks · doi:10.1159/000102632 · Cited by 6
Self-citationTargeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan
Antoniu, S. A. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.9.1077 · Cited by 7
“In bleomycin-induced lung fibrosis in mice N -acetylcysteine reduced collagen pulmonary deposition and in a Phase III clinical study, N -acetylcysteine added to the conventional therapy did not improve survival or exercise capacity but reduced lung function decline [48,49] .”
BackgroundRoig, V., Herrero, A., Arroyo-Cózar, M., Vielba, D., Martínez, S. A. J., & Macías, E. (2010) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(10)70004-5 · Cited by 6
Corte, T. J., du Bois, R. M., & Wells, A. U. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00065-8 · Cited by 6
First drug for idiopathic pulmonary fibrosis approved in Japan
(2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2767 · Cited by 6
Behr, J., Bonella, F., Frye, B. C., Günther, A., Hagmeyer, L., Henes, J., Klemm, P., Koschel, D., Kreuter, M., Leuschner, G., et al. (2024) · Respiration · doi:10.1159/000540856 · Cited by 13
“…on the effect of N-acetylcysteine in combination with azathioprine (AZA) and prednisone or as monotherapy in patients with IPF were conducted [82, 83], in which no convincing effect of N-acetylcysteine on FVC was seen, further studies have investigated the effectiveness of N-acetylcysteine…”
Self-citationN-acetylcysteine Clinical Applications
Yahia, Z., Yahia, A., & Abdelaziz, T. (2024) · Cureus · doi:10.7759/cureus.72252 · Cited by 12
“Disease development was greatly halted as evaluated by vital capacity and diffusing capacity [52,53].”
BackgroundSambataro, D., Morina, G., Libra, A., Palmucci, S., Pallotti, F., Geraci, G., Rocca, G. L., Ferro, F., Moretti, M., Baldini, C., et al. (2025) · Medicina · doi:10.3390/medicina61040599 · Cited by 9
“…deterioration of pulmonary function com ‐ pared with Azathioprine plus Prednisolone alone, with similar adverse e ff ects but also with a similar mortality (9% and 11%, respectively) [21]. plus Prednisolone alone, with similar adverse effects but a similar mortality (9% and 11%, respectively) [21].”
The Challenges of Clinical Research in Orphan Diseases
Spagnolo, P., & du Bois, R. M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2401-6_2 · Cited by 5
Fernández‐Fernández, F. J., & Sesma, P. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.101159 · Cited by 5
Idiopathic Interstitial Pneumonias
Selman, M., Morrison, L. D., Noble, P. W., & King, T. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00057-2 · Cited by 9
The road to hell is paved with good intentions: a look back at the PANTHER-IPF trial
Kam, M. L. W., Caliez, J., Nunès, H., & Gille, T. (2022) · Breathe · doi:10.1183/20734735.0074-2022 · Cited by 6
Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives
Vancheri, C., Sciacca, E., Muscato, G., Spicuzza, L., Fruciano, M., Gili, E., Sambataro, G., Palmucci, S., & Libra, A. (2024) · Multidisciplinary Respiratory Medicine · doi:10.5826/mrm.2024.982 · Cited by 14
“…Diffusing Capacity of the Lungs for Carbon Monoxide (DL CO ) among patients treated with NAC, although no improvement in one-year survival was observed [29]. cells and polymorphonuclear leukocytes, and able to increase collagen production and reduce synthesis of interstitial collagenase [35–38].”
BackgroundIdiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
Tourin, O., Swigris, J. J., & Olson, A. L. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_2 · Cited by 5
Rheumatoid Arthritis Interstitial Lung Disease
Vinik, O., Marras, T. K., Shapera, S., & Mittoo, S. (2011) · InTech eBooks · doi:10.5772/27626 · Cited by 5
“While limited evidence supports its efficacy in patients with IPF (Demedts et al., 2005), there is currently no evidence-based rationale for its use in RA- ILD.”
BackgroundInfluentialLow-molecular-weight S-nitrosothiols and blood vessel injury
Marsden, P. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33136 · Cited by 5
Li, M., Wang, S., Fan, M., Li, Z., & Huang, Y. (2006) · PubMed · Cited by 7
Raghu, G., Rochwerg, B. N., Zhang, Y., García, C. Á., Azuma, A., Behr, J., Brożek, J., Collard, H. R., Cunningham, W. E., Homma, S. A., et al. (2015) · Cited by 9
Self-citationMa, M., Wu, C., Zhang, P., Li, T., Wei, S., Yu, B., Qin, F., & Yuan, J. (2020) · Asian Journal of Andrology · doi:10.4103/aja.aja_17_20 · Cited by 7
Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment
Assar, S., Khazaei, H., Naseri, M., El‐Senduny, F. F., Momtaz, S., Farzaei, M. H., & Echeverría, J. (2021) · Journal of Immunology Research · doi:10.1155/2021/9920416 · Cited by 7
Chen, G., & Lu, H. (2022) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2022.01032 · Cited by 5
Therapie der Lungenfibrose: Neue Substanzen, neue Interventionen
Costabel, U., & Bonella, F. (2011) · Der Internist · doi:10.1007/s00108-011-2926-0 · Cited by 10
Self-citationSimple Answers to Complex Questions about Mucolytics for Children
Simonova, O. I. (2015) · Вопросы современной педиатрии · doi:10.15690/vsp.v14.i4.1391 · Cited by 5
Öztay, F., Kayalar, Ö., & Yıldırım, M. (2019) · Springer eBooks · doi:10.1007/978-981-13-8413-4_17 · Cited by 6
Peces‐Barba, G., & Heili-Frades, S. B. (2007) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(07)71170-5 · Cited by 6
Fibrose pulmonaire idiopathique : prise en charge diagnostique et thérapeutique en 2013
Israël‐Biet, D., Juvin, K., Tran, K. D., Badia, A., Cazes, A., & Delclaux, C. (2014) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2013.12.004 · Cited by 8
Pharmacotherapy in patients with idiopathic pulmonary fibrosis
Nagai, S., Handa, T., & Kim, D. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.11.1909 · Cited by 5
“This encouraging result led to the Idiopathic Pulmonary Fibrosis International Group Exploring N -Acetyl Cysteine I Annual Study: this was a randomized control trial to investigate the effects of N -acetylcysteine in combination with prednisolone and azathioprine on the pulmonary function in patients with IPF [73] .”
ResultPrasse, A., Holle, J. U., & Müller–Quernheim, J. (2009) · Der Internist · doi:10.1007/s00108-009-2406-y · Cited by 9
Identifying Patients with Idiopathic Pulmonary Fibrosis
Richeldi, L., & Abraham, E. H. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200612-1873ed · Cited by 5
Matics, Z., Bardóczi, A. B., Galkó, C., Szabó, B., Gede, N., Molnár, Z., Duray, G. Z., Turan, C., Hegyi, P., Horváth, G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102966 · Cited by 4
What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?
Moua, T., Baqir, M., & Ryu, J. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216304 · Cited by 9
“…antagonists), sildenafil (phosphodiesterase-5 inhibitor) [12], imatinib mesylate (tyrosine kinase inhibitor) [13], N-acetylcysteine (anti-oxidant) [14], warfarin (anti-coagulant) [15], ziritaxestat (autotaxin inhibitor) [16], simtuzumab (lysyl oxidase inhibitor) [17], and pamrevlumab (human…”
Leask, A. (2013) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-013-0205-7 · Cited by 4
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
Spagnolo, P., Luppi, F., Montanari, G., & Richeldi, L. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_14 · Cited by 4
Steiner, C. A., & Higgins, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_23 · Cited by 6
Fang, H., Dong, T., Han, Z., Li, S., Liu, M., Liu, Y., Yang, Q., Fu, M., & Zhang, H. (2023) · International Journal of COPD · doi:10.2147/copd.s426763 · Cited by 6
Tang, C., Wang, L., Chen, Z., Yang, J. P., Gao, H., Guan, C., Gu, Q., He, S., Yang, F., Chen, S., et al. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s438044 · Cited by 6
Effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis
Munson, J. C., Kreider, M. E., Chen, Z., Christie, J. D., & Kimmel, S. E. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03670.x · Cited by 6
[Lung biopsy for the diagnosis of interstitial lung disease].
Quadrelli, S., Lyons, G., Ciallella, L. M., Iotti, A., & Chertcoff, J. (2007) · PubMed · Cited by 4
Innovations thérapeutiques de la fibrose pulmonaire idiopathique
Uzunhan, Y., Nunès, H., Gille, T., Bron, C., Planès, C., & Valeyre, D. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.07.009 · Cited by 6
Die idiopathische Lungenfibrose
Prasse, A. (2015) · Pneumologie · doi:10.1055/s-0034-1393036 · Cited by 5
Interstitial Lung Disease in Systemic Sclerosis
Wells, A. U., Margaritopoulos, G. A., Antoniou, K. M., & Nicholson, A. G. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2401-6_25 · Cited by 5
Self-citationFibrose pulmonar idiopática: uma década de progressos
Swigris, J. J., & Brown, K. K. (2006) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132006000300012 · Cited by 7
Blocking endothelin: breaking new ground
du Bois, R. M. (2007) · European Respiratory Review · doi:10.1183/09059180.00010206 · Cited by 5
The Intersection between Immune System and Idiopathic Pulmonary Fibrosis—A Concise Review
Liu, H., Cui, H., & Liu, G. (2025) · Fibrosis · doi:10.70322/fibrosis.2025.10004 · Cited by 7
“The 2005 IFIGENIA trial, published in the New England Journal of Medicine, suggested that adding high-dose NAC to prednisone and azathioprine helped preserve vital capacity and lung diffusion in IPF patients [16].”
Lithium carbonate induces myofibroblast necroptosis to reverse pulmonary fibrosis
Wei, K., Tang, L., Zhang, X., Liu, S., Tong, S., Bian, Y., Ma, Y., Zhu, T., Xiao, J., Lin, Q., et al. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00002-4 · Cited by 3
“In line with this, recent clinical trials have shown that both respiratory failure and mortality are increased in patients with PF receiving a combination of anti-inflammatory and immunosuppressive treatments [57, 58].”
Therapie der idiopathischen interstitiellen Pneumonien
Prasse, A., & Müller–Quernheim, J. (2006) · Der Internist · doi:10.1007/s00108-006-1734-4 · Cited by 3
Wells, A. U., Ward, S. P., & Cramer, D. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9771-5_5 · Cited by 3
Idiopathic fibrotic lung disease at a university hospital setting: management and prognostic factors
Rad, P., Karlsson, C.-A., & Janson, C. (2015) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v2.26915 · Cited by 3
“It has been suggested that Nacetylcysteine (NAC) given at high doses has a beneficial effect on lung function in IPF (9); however, a recent randomized controlled trial failed to show such an effect (10).”
BackgroundManagement of idiopathic pulmonary fibrosis: A survey of Canadian respirologists
Fidler, L. M., Burns, K. E. A., Singer, L. G., Kiss, A., Shapera, S., & Stanbrook, M. B. (2020) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2020.1767524 · Cited by 3
Research Progress of Rheumatoid Arthritis Combined with Lung Interstitial Disease
王, 英. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381714 · Cited by 3
Mathur, T., & Singh, I. (2023) · Current Drug Research Reviews · doi:10.2174/0125899775269970231218100959 · Cited by 3
Bastan, F., & Kazemeini, M. (2024) · Chemical Engineering and Processing - Process Intensification · doi:10.1016/j.cep.2024.109928 · Cited by 3
Chung, M. P. (2006) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2006.61.4.321 · Cited by 3
A COPD Patient Who Developed Pulmonary Fibrosis Following COVID-19: A Case Study
Pezzuto, A., Tonini, G., Tammaro, A., Laviano, A., Salerno, G., & Ciccozzi, M. (2021) · Global Journal of Respiratory Care · doi:10.12974/2312-5470.2021.07.06 · Cited by 3
“Although there is currently no clinical data on the frequency and mechanism of post-COVID-19 pulmonary fibrosis, it is deemed to affect around onethird of the patients hospitalized with SARS-COV-2 [14, 15].”
BackgroundMehrian, P., Cheraghvandi, A., Droudnia, A., Talischi, F., Tafti, S. F., Kahkouee, S., & Jamaati, H. (2014) · Europe PMC (PubMed Central) · Cited by 3
Bosentan et fibrose pulmonaire
Cottin, V., & Cordier, J. F. (2007) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(07)80022-1 · Cited by 3
Somatostatin analogs for idiopathic pulmonary fibrosis therapy
Antoniu, S. A. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.7.1137 · Cited by 3
“It was found to reduce lung function decline in IPF subjects despite having no effect on survival [5,6] .”
BackgroundTreatment of Idiopathic Pulmonary Fibrosis: A European Perspective
Hoyles, R. K., & du Bois, R. M. (2006) · Clinical Pulmonary Medicine · doi:10.1097/01.cpm.0000198144.90287.1f · Cited by 3
Branley, H. M., & Lake, F. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.622 · Cited by 3
Kubo, N., Araki, K., Yamanaka, T., Hoshino, K., Ishii, N., Tsukagoshi, M., Igarashi, T., Watanabe, A., Hirai, K., Saitoh, F., et al. (2017) · Surgery Today · doi:10.1007/s00595-017-1489-7 · Cited by 3
“For perioperative administration to prevent AE, macrolides [24, 25], N-acetylcysteine [26, 27], and proteinase inhibitors [28] have been reported to be useful.”
BackgroundSleep-Related Disorders in Chronic Pulmonary Disease
Hakim, A. D., & Littner, M. R. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1703-7.10021-0 · Cited by 4
Metadata
- Authors
- Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D. R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M. M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., & Montanari, M.
- Affiliations
- KU Leuven (BE)
- LMU Klinikum (DE)
- Johannes Gutenberg University Mainz (DE)
- Ruhrlandklinik (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Edinburgh (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Royal Brompton Hospital (GB)
- Hôpital Antoine-Béclère (FR)
- University of Pisa (IT)
- Zambon (Italy) (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2229-2242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125322938
- Cited by
- 964
- References
- 48
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 33 · 2023: 32 · 2022: 17 · 2021: 29 · 2020: 28 · 2019: 26 · 2018: 24 · 2017: 31 · 2016: 49 · 2015: 64 · 2014: 63 · 2013: 72 · 2012: 79
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, N-acetylcysteine, usual interstitial pneumonia, prednisone, azathioprine, vital capacity, diffusing capacity for carbon monoxide, lung function decline, mortality, myelosuppression, antioxidant therapy, disease-modifying therapy, treatment efficacy and safety, adverse events
- MeSH terms
- Acetylcysteine, Aged, Anti-Inflammatory Agents, Antioxidants, Azathioprine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prednisone, Pulmonary Diffusing Capacity, Pulmonary Fibrosis, Vital Capacity, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.